Clinical trial
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in…
NCT00189917 · Bavarian Nordic, Industry · Completed
Key facts
| NCT number | NCT00189917 |
|---|---|
| Title | Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders |
| Official title | An Open-label, Controlled Phase I Pilot Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in 18-40 Year Old Vaccinia-naïve Subjects With Atopic Disorders |
| Lead sponsor | Bavarian Nordic, Industry |
| Collaborators | National Institute of Allergy and Infectious Diseases (NIAID) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Dermatitis, Atopic, Hay Fever |
| Intervention type | Biological |
| Interventions | IMVAMUNE (MVA-BN) |
| Enrollment | 60 |
| Start date | Apr 1, 2004 |
| Primary completion | Dec 1, 2005 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 10, 2019 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: